| 货号 | 4586-KS-010 |
| 别名 | Cancer Osaka thyroid oncogene; c-COT; cot (cancer Osaka thyroid) oncogene; COT; COTMEKK8; EC 2.7.11.25; EST; ESTF; ESTFLJ10486; Ewing sarcoma transformant; MAP3K8; mitogen-activated protein kinase kinase kinase 8; Proto-oncogene c-Cot; proto-oncogene serine/threoine protein kinase; Serine/threonine-protein kinase cot; TPL2; Tpl-2; Tumor progression locus 2; tumor progression locus-2 | 全称 | Mitogen-activated Protein Kinase Kinase Kinase 8 |
| 反应种属 | Human |
| 来源 | Spodoptera frugiperda,Sf 9 (baculovirus)-derived aa 30-397 Accession # NM_005204 |
| 产品组分 |
| 供应商 | R&D Systems |
| Entrez Gene IDs | 1326 (Human); 26410 (Mouse); 116596 (Rat) |
| 生物活性 | The activity of COT is typically 860-1164 nmol/min/mg using MEK1 and ERK1 substrates and a myelin basic protein (MBP) substrate (see Activity Assay Protocol). |
| 背景 | COT is an oncogene that can activate both the MAP kinase and JNK kinase pathways. COT activates I kappa B kinases and induces the nuclear production of NF-kappa B. The C-terminal catalytic domain of KSR2 associates with COT and KSR2 can negatively regulate the kinase activity of COT in vitro. Co-transfection of KSR2 with COT in cells lead to reduced COT-mediated ERK activation and COT induced IL-8 production in a dose-dependent manner (1). COT is one of the MAP kinase kinase (MAPKK) kinases that regulates the ERK1/ERK2 pathway in response to IL-1. Blockage of expression of COT results in failure of IL-1 to induce an increase in IL 8 and MIP-1 beta mRNA levels (2). |
| Accession # | NM_005204 |
| 运输条件 | Dry Ice |
| N-terminal Sequence Analysis | Using an N-terminal GST tag |
| SDS-PAGE | 70 kDa |
| 存放说明 | -80℃ |
| 纯度 | >70%, by SDS-PAGE under reducing conditions and visualized by Colloidal Coomassie® Blue stain at 5 μg per lane |
| 参考文献 |
|
The approximate molecular weight is 70 kDa and the average purity is 75%. |
